AC Immune SA

ACIU

CH0329023102

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-13 EDT			5-day change	1st Jan Change
1.950 ^USD	-5.80%		-4.41%	-27.78%

06-11	AC Immune SA Announces Executive Changes	CI
05-19	AC Immune SA Announces Not Stand for Re-Election of Board of Directors	CI

Sector Update: Health Care

Published on 2024-05-13 at 15:37, updated on 2024-05-13 at 15:38

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AC Immune SA

AC Immune SA Announces Executive Changes	06-11	CI
AC Immune SA Announces Not Stand for Re-Election of Board of Directors	05-19	CI
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update	04-30	RE
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date	04-02	RE
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
AC Immune SA Announces Management Changes, Effective from January 1, 2025	12-18	CI
AC Immune Reports Interim Safety Data from Phase 1b/2 Abate Trial of ACI-24.060 in Down Syndrome	12-10	CI
Sector Update: Health Care Stocks Weaker Late Afternoon	11-14	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	11-14	MT
AC Immune Shares Gain Following Positive Clinical Results of Potential Parkinson's Treatment	11-14	MT
Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson?S Disease	11-14	CI
Earnings Flash (ACIU) AC IMMUNE SA Reports Q3 Revenue $25.5M	11-05	MT
Earnings Flash (ACIU) AC IMMUNE SA Reports Q3 EPS $0.05	11-05	MT
Earnings Flash (ACIU) AC IMMUNE SA Reports Q3 EPS $0.05	11-05	MT
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-05	CI
AC Immune SA(NasdaqGM:ACIU) added to S&P Global BMI Index	24-09-22	CI
AC Immune SA Announces Executive Changes	24-09-19	CI
Sector Update: Health Care Stocks Steady Premarket Tuesday	24-09-17	MT
Sector Update: Health Care	24-09-17	MT
AC Immune Expects $29 Million Milestone Payment From Janssen	24-09-17	MT
AC Immune's Partner Life Molecular Gets FDA Fast Track Designation for PET Imaging Agent	24-08-28	MT
AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan	24-08-28	DJ
AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
AC Immune SA Unveils A Novel Class of Neurodegenerative Disease-Fighting Drug-Tridates Called morADC (Morphomer Antibody Drug Conjugate)	24-07-31	CI

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimerâs disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Employees

153

Sector

Biotechnology & Medical Research

Calendar

06-18 - Annual General Meeting

More about the company